{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:05:55Z","timestamp":1756425955284,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,28]]},"DOI":"10.7759\/cureus.91192","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:58:07Z","timestamp":1756403887000},"source":"Crossref","is-referenced-by-count":0,"title":["Initial Investigation of Vericiguat Efficacy in the Treatment of Recurrently Hospitalised Heart Failure Patients"],"prefix":"10.7759","author":[{"given":"Aleksandrs","family":"Vasiljevs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlis","family":"Trusinskis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.12.001","article-title":"Costs of care and financial hardship among patients with heart failure","volume":"269","author":"Gunn AH","year":"2024","unstructured":"Gunn AH, Warraich HJ, Mentz RJ. Costs of care and financial hardship among patients with heart failure. Am Heart J. 2024, 269:94-107. 10.1016\/j.ahj.2023.12.001","journal-title":"Am Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad026","article-title":"Corrigendum to: Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"119","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH. Corrigendum to: Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 119:1453. 10.1093\/cvr\/cvad026","journal-title":"Cardiovasc Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae110","article-title":"Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021","volume":"11","author":"Chen QF","year":"2025","unstructured":"Chen QF, Chen L, Katsouras CS, et al.. Global burden of heart failure and its underlying causes in 204 countries and territories, 1990-2021. Eur Heart J Qual Care Clin Outcomes. 2025, 11:493-509. 10.1093\/ehjqcco\/qcae110","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2021.05.009","article-title":"Advanced heart\u00a0failure epidemiology and outcomes: a population-based study","volume":"9","author":"Dunlay SM","year":"2021","unstructured":"Dunlay SM, Roger VL, Killian JM, et al.. Advanced heart\u00a0failure epidemiology and outcomes: a population-based study. JACC Heart Fail. 2021, 9:722-32. 10.1016\/j.jchf.2021.05.009","journal-title":"JACC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.05.007","article-title":"Hypotension at heart failure discharge: should it be a limiting factor for drug titration?","volume":"386","author":"Melendo-Viu M","year":"2023","unstructured":"Melendo-Viu M, Dobarro D, March\u00e1n L\u00f3pez \u00c1, et al.. Hypotension at heart failure discharge: should it be a limiting factor for drug titration?. Int J Cardiol. 2023, 386:59-64. 10.1016\/j.ijcard.2023.05.007","journal-title":"Int J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03527-x","article-title":"Relationship between comorbidity and health outcomes in patients with heart failure: a systematic review and meta-analysis","volume":"23","author":"Lee KS","year":"2023","unstructured":"Lee KS, Park DI, Lee J, Oh O, Kim N, Nam G. Relationship between comorbidity and health outcomes in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023, 23:498. 10.1186\/s12872-023-03527-x","journal-title":"BMC Cardiovasc Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.glohj.2023.07.004","article-title":"Impact of vericiguat on heart failure with reduced ejection fraction: a review","volume":"7","author":"Vohra M","year":"2023","unstructured":"Vohra M, Amir M, Osoro I, Sharma A, Kumar R. Impact of vericiguat on heart failure with reduced ejection fraction: a review. Global Health J. 2023, 7:123-9. 10.1016\/j.glohj.2023.07.004","journal-title":"Global Health J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab670","article-title":"Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. Corrigendum to: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021, 42:4901. 10.1093\/eurheartj\/ehab670","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong PW","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, et al.. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020, 382:1883-93. 10.1056\/NEJMoa1915928","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.59931\/rcp.23.0001","article-title":"Mortality and hospitalization rate of heart failure patients with preserved ejection fraction treated with dapagliflozin vs. empagliflozin","volume":"1","author":"Tam JC","year":"2023","unstructured":"Tam JC, Cheng FW, So AI. Mortality and hospitalization rate of heart failure patients with preserved ejection fraction treated with dapagliflozin vs. empagliflozin. Res Clin Pharm. 2023, 1:127-36. 10.59931\/rcp.23.0001","journal-title":"Res Clin Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of\u00a0medicines following a first heart\u00a0failure\u00a0hospitalization: EVOLUTION HF","volume":"11","author":"Bozkurt B","year":"2023","unstructured":"Bozkurt B, Savarese G, Adamsson Eryd S, et al.. Mortality, outcomes, costs, and use of\u00a0medicines following a first heart\u00a0failure\u00a0hospitalization: EVOLUTION HF. JACC Heart Fail. 2023, 11:1320-32. 10.1016\/j.jchf.2023.04.017","journal-title":"JACC Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.05.040","article-title":"Global comparison of readmission rates for patients with heart\u00a0failure","volume":"82","author":"Foroutan F","year":"2023","unstructured":"Foroutan F, Rayner DG, Ross HJ, et al.. Global comparison of readmission rates for patients with heart\u00a0failure. J Am Coll Cardiol. 2023, 82:430-44. 10.1016\/j.jacc.2023.05.040","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000872","article-title":"Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF","volume":"7","author":"Patel PA","year":"2014","unstructured":"Patel PA, Heizer G, O'Connor CM, et al.. Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. Circ Heart Fail. 2014, 7:918-25. 10.1161\/CIRCHEARTFAILURE.113.000872","journal-title":"Circ Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy","volume":"25","author":"Pieske B","year":"2023","unstructured":"Pieske B, Pieske-Kraigher E, Lam CS, et al.. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy. Eur J Heart Fail. 2023, 25:1012-21. 10.1002\/ejhf.2836","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.04.015","article-title":"Sequential evaluation of NT-proBNP in heart\u00a0failure: insights into clinical outcomes and efficacy of vericiguat","volume":"10","author":"Armstrong PW","year":"2022","unstructured":"Armstrong PW, Zheng Y, Troughton RW, et al.. Sequential evaluation of NT-proBNP in heart\u00a0failure: insights into clinical outcomes and efficacy of vericiguat. JACC Heart Fail. 2022, 10:677-88. 10.1016\/j.jchf.2022.04.015","journal-title":"JACC Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010661","article-title":"Evolution of NT-proBNP during prerandomization screening in VICTORIA: implications for clinical outcomes and efficacy of vericiguat","volume":"16","author":"Armstrong PW","year":"2023","unstructured":"Armstrong PW, Zheng Y, Lund LH, et al.. Evolution of NT-proBNP during prerandomization screening in VICTORIA: implications for clinical outcomes and efficacy of vericiguat. Circ Heart Fail. 2023, 16:e010661. 10.1161\/CIRCHEARTFAILURE.123.010661","journal-title":"Circ Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/398950-initial-investigation-of-vericiguat-efficacy-in-the-treatment-of-recurrently-hospitalised-heart-failure-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:58:08Z","timestamp":1756403888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/398950-initial-investigation-of-vericiguat-efficacy-in-the-treatment-of-recurrently-hospitalised-heart-failure-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.91192","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}